Trevi Therapeutics (NASDAQ:TRVI) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVIFree Report) in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a $8.00 target price on the stock.

Separately, Oppenheimer reiterated an outperform rating and issued a $9.00 price target on shares of Trevi Therapeutics in a research note on Thursday, March 21st.

Get Our Latest Research Report on Trevi Therapeutics

Trevi Therapeutics Stock Performance

Shares of Trevi Therapeutics stock opened at $2.73 on Wednesday. The firm has a 50-day moving average of $3.03 and a 200-day moving average of $2.07. Trevi Therapeutics has a 52-week low of $0.97 and a 52-week high of $4.00. The stock has a market cap of $192.29 million, a PE ratio of -8.03 and a beta of 0.91.

Trevi Therapeutics (NASDAQ:TRVIGet Free Report) last issued its quarterly earnings data on Wednesday, March 20th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.02. Equities research analysts predict that Trevi Therapeutics will post -0.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

A number of large investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Trevi Therapeutics in the 3rd quarter valued at approximately $43,000. Oppenheimer & Co. Inc. acquired a new position in Trevi Therapeutics during the first quarter valued at approximately $208,000. Silverarc Capital Management LLC raised its position in Trevi Therapeutics by 4.7% during the third quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company’s stock valued at $2,022,000 after purchasing an additional 41,491 shares in the last quarter. Opaleye Management Inc. lifted its stake in Trevi Therapeutics by 48.6% during the fourth quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock worth $3,397,000 after purchasing an additional 829,100 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after purchasing an additional 60,249 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

(Get Free Report)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

Recommended Stories

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.